PDF herunterladen
Zentralbl Chir 2021; 146(02): 176-187
DOI: 10.1055/a-1309-2368
Übersicht

Die konservative Therapie der Refluxkrankheit und ihre Grenzen

Conservative Therapy of Reflux Disease and its Limits
Joachim Labenz
Innere Medizin, Diakonie Klinikum, Jung-Stilling-Krankenhaus Siegen, Deutschland
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die gastroösophageale Refluxkrankheit (GERD) ist häufig. Protonenpumpeninhibitoren (PPI) gelten als Mittel der ersten Wahl für alle klinischen Manifestationen. Sie wirken allerdings bei mindestens 30% der Patienten unzureichend, zudem werden sie gelegentlich auch nicht vertragen. Einige Patienten wünschen sich auch eine therapeutische Alternative. Alginate bewirken eine mechanische Refluxhemmung durch Bildung einer gelartigen Schicht in der sog. Acid Pocket, einem Säurereservoir, das unmittelbar nach der Nahrungsaufnahme auf dem Speisebrei im Magenkorpus entsteht. Sie kommen zur Symptombehandlung einer unkomplizierten GERD als Alternative und bei unzureichendem PPI-Effekt auf die Symptome auch als Ergänzung zu einem PPI (add-on) in Betracht. Bei persistierenden Refluxbeschwerden sowie einer nicht heilenden Refluxösophagitis ist eine differenzierte endoskopische und funktionsanalytische Diagnostik zur Ursachenklärung erforderlich. Extraösophageale Manifestationen der GERD, wie z. B. Husten, Räusperzwang, Stimmprobleme und Globusgefühl, sprechen häufig nicht auf eine Antirefluxtherapie an. Neue Daten sprechen dafür, dass es sich um komplexe Hypersensitivitätssyndrome handelt, bei denen Reflux nur einer von mehreren möglichen Auslösern ist.

Abstract

Gastrooesophageal reflux disease (GORD) is common. Proton pump inhibitors (PPI) are regarded as first line therapy for all clinical manifestations. However, their efficacy is inadequate for at least 30% of patients and they are occasionally poorly tolerated. Moreover, some patients would prefer an alternative therapy. Alginate cause mechanical reflux inhibition by forming a gelatinous layer in the so-called acid pocket, an acid reservoir that forms on the surface of the chyme in the gastric corpus immediately after food intake. They may be used an alternative to treat the symptoms of uncomplicated GORD and as an add-on to PPIs if these do not improve symptoms adequately. If the reflux symptoms persist or if reflux oesophagitis does not heal, differentiated diagnostic testing must be performed, using endoscopy and functional analysis. Extraoesophageal manifestations of GORD include cough, compulsive clearing of the throat, problems with the voice and globus sensation. These often do not respond to antireflux therapy. Recent data indicate that these are complex hypersensitivity syndromes and that reflux is only one of several possible triggers.

Schlüsselwörter

Alginat - extraösophageale Symptome - GERD - Protonenpumpeninhibitor

Key words

alginate - extraesophageal symptoms - GORD - proton pump inhibitor


Publikationsverlauf

Artikel online veröffentlicht:
17. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Vakil N, van Zanten SV, Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920
    CrossrefPubMedGoogle Scholar
  • 2 Labenz J, Labenz C. Prävalenz und natürlicher Verlauf der gastroösophagealen Refluxkrankheit. Gastroenterologe 2016; 11: 102-109
    CrossrefPubMedGoogle Scholar
  • 3 El-Serag HB, Sweet S, Winchester CC. et al. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2014; 63: 871-880
    CrossrefPubMedGoogle Scholar
  • 4 Boeckxstaens G, El-Serag HB, Smout AJPM. et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014; 63: 1185-1193
    CrossrefPubMedGoogle Scholar
  • 5 Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of gastroesophageal reflux disease: where Rome, Lyon, and Montreal meet. Clin Gastroenterol Hepatol 2020; 18: 767-776
    CrossrefPubMedGoogle Scholar
  • 6 Dunbar KB, Agoston AT, Odze RD. et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA 2016; 315: 2104-2112
    CrossrefPubMedGoogle Scholar
  • 7 Kulig M, Nocon M, Vieth M. et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-589
    CrossrefPubMedGoogle Scholar
  • 8 Koop H, Fuchs KH, Labenz J. et al. [S2 k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013]. Z Gastroenterol 2014; 52: 1299-1346
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Ness-Jensen E, Lindam A, Lagergren J. et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2013; 108: 376-382
    CrossrefPubMedGoogle Scholar
  • 10 Triadafilopoulos G, Korzilius JW, Zikos T. et al. Ninety-six hour wireless esophageal pH study in patients with GERD shows that restrictive diet reduces esophageal acid exposure. Dig Dis Sci 2020; 65: 2331-2344
    CrossrefPubMedGoogle Scholar
  • 11 Labenz J, Koop H. Gastroösophageale Refluxkrankheit – was tun, wenn PPI nicht ausreichend wirksam, verträglich oder erwünscht sind?. Dtsch Med Wochenschr 2017; 142: 356-366
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Mössner J. The indications, applications, and risks of proton pump inhibitors – a review after 25 years. Dtsch Arztebl Int 2016; 113: 477-483
    PubMedGoogle Scholar
  • 13 Spechler SJ. Proton pump inhibitors: what the internist needs to know. Med Clin North Am 2019; 103: 1-14
    CrossrefPubMedGoogle Scholar
  • 14 Attwood SE, Ell C, Galmiche JP. et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015; 41: 1162-1174
    CrossrefPubMedGoogle Scholar
  • 15 Moayyedi P, Eikelboom JW, Bosch J. et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019; 157: 682-691
    CrossrefPubMedGoogle Scholar
  • 16 Jackson MA, Goodrich JK, Maxan ME. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65: 749-756
    CrossrefPubMedGoogle Scholar
  • 17 Kurlander JE, Kennedy JK, Rubinstein JH. et al. Patientsʼ perceptions of proton pump inhibitor risks and attempts at discontinuation: a national survey. Am J Gastroenterol 2019; 114: 244-249
    CrossrefPubMedGoogle Scholar
  • 18 Kurlander JE, Rubinstein JH, Richardson CR. et al. Physicanʼs perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey. Am J Gastroenterol 2020; 115: 689-696
    CrossrefPubMedGoogle Scholar
  • 19 Fletscher J, Wirz A, Young J. et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-783
    CrossrefPubMedGoogle Scholar
  • 20 Mitchell DR, Derakhshan MH, Robertson EV. et al. The role of the acid pocket in gastroesophageal reflux disease. J Clin Gastroenterol 2016; 50: 111-119
    CrossrefPubMedGoogle Scholar
  • 21 Beaumont H, Bennink RJ, de Jong J. et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441-451
    CrossrefPubMedGoogle Scholar
  • 22 Rohof WO, Bennink RJ, Smout AJ. et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11: 1585-1591
    CrossrefPubMedGoogle Scholar
  • 23 Woodland P, Batista-Lima F, Lee C. et al. Topical protection of human esophageal mucosal integrity. Am J Physiol Gastrointest Liver Physiol 2015; 308: G975-G980
    CrossrefPubMedGoogle Scholar
  • 24 Sauer M, Fox MR. [The acid pocket – a novel target for the treatment of gastro-esophageal reflux disease]. Z Gastroenterol 2018; 56: 1276-1282
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 25 Strugala V, Dettmar PW, Sarratt K. et al. A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med Res 2010; 38: 449-457
    CrossrefPubMedGoogle Scholar
  • 26 Thomas E, Wade E, Crawford G. et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595-602
    CrossrefPubMedGoogle Scholar
  • 27 Leiman DA, Riff BP, Morgan S. et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus 2017; 30: 1-9
    CrossrefPubMedGoogle Scholar
  • 28 Pouchain D, Bigard MA, Liard F. et al. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial. BMC Gastroenterol 2012; 23: 12-18
    PubMedGoogle Scholar
  • 29 Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Ther 2020; 51: 421-434
    CrossrefPubMedGoogle Scholar
  • 30 George N, Abdallah J, Maradey-Romero C. et al. Review article: the current treatment of non-cardiac chest pain. Aliment Pharmacol Ther 2016; 43: 213-239
    CrossrefPubMedGoogle Scholar
  • 31 El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-737
    CrossrefPubMedGoogle Scholar
  • 32 Labenz J, Labenz G, Stephan D. et al. Unzureichende Symptomkontrolle unter Langzeittherapie mit PPI bei GERD – Fakt oder Fiktion?. MMW Fortschr Med 2016; 158 (Suppl. 04) S7-S11
    CrossrefPubMedGoogle Scholar
  • 33 Delshad SD, Almario CV, Chey WD. et al. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology 2020; 158: 120-1261
    CrossrefPubMedGoogle Scholar
  • 34 Spechler SJ, Hunter JG, Jones KM. et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med 2019; 381: 1513-1523
    CrossrefPubMedGoogle Scholar
  • 35 Kahrilas PJ, Keefer L, Pandolfino JE. Patients with refractory reflux symptoms: what do they have and how should they be managed?. Neurogastroenterol Motil 2015; 27: 1195-1201
    CrossrefPubMedGoogle Scholar
  • 36 Kirchheiner J, Glatt S, Fuhr U. et al. Relative potency of proton-pump inhibitors – comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19-31
    CrossrefPubMedGoogle Scholar
  • 37 Gyawali CP, Kahrilas PJ, Savarino E. et al. Modern diagnosis of GERD: the Lyon consensus. Gut 2018; 67: 1351-1362
    CrossrefPubMedGoogle Scholar
  • 38 Fuchs KH, Musial F, Ulbricht F. et al. Foregut symptoms, somatoform tendencies, and the selection of patients for antireflux surgery. Dis Esophagus 2017; 30: 1-10
    CrossrefPubMedGoogle Scholar
  • 39 Spechler SJ. Evaluation and treatment of patients with persistent reflux symptoms despite proton pump inhibitor treatment. Gastroenterol Clin North Am 2020; 49: 437-450
    CrossrefPubMedGoogle Scholar
  • 40 Schey R, Dickman R, Parthasarathy S. et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. Gastroenterology 2007; 133: 1787-1795
    CrossrefPubMedGoogle Scholar
  • 41 Manabe N, Haruma K, Ito M. et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012; 25: 373-380
    CrossrefPubMedGoogle Scholar
  • 42 Reimer C, Lodrup AB, Smith G. et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther 2016; 43: 899-909
    CrossrefPubMedGoogle Scholar
  • 43 Müller M, Labenz G, Borkenstein DP. et al. [Alginate on demand as add-on for patients with gastro-oesophageal reflux disease and insufficient PPI effect]. Dtsch Med Wochenschr 2019; 144: e30-e35
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 44 Weijenborg PW, de Schepper HS, Smout AJ. et al. Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2015; 13: 251-259
    CrossrefPubMedGoogle Scholar
  • 45 Labenz J, Gross M. [Gastroesophageal reflux disease beyond PPI]. MMW Fortschr Med 2018; 160: 40-44
    PubMedGoogle Scholar
  • 46 Hunt RH, Yuan Y, Scarpignato C. Editorial: healing of refractory reflux oesophagitis–an ongoing unmet clinical need. Aliment Pharmacol Ther 2014; 40: 987-989
    CrossrefPubMedGoogle Scholar
  • 47 Vaezi MF, Katzka D, Zerbib F. Extraesophageal symptoms and diseases attributed to GERD: where is the pendulum swinging now?. Clin Gastroenterol Hepatol 2018; 16: 1018-1029
    CrossrefPubMedGoogle Scholar
  • 48 Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22: 65-70
    CrossrefPubMedGoogle Scholar
  • 49 Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung 2010; 188 (Suppl. 01) S87-S90
    CrossrefPubMedGoogle Scholar
  • 50 Desjardin M, Roman S, Bruley des Varannes S. et al. Pharyngeal pH alone is not reliable for the detection of pharyngeal reflux events: A study with oesophageal and pharyngeal pH-impedance monitoring. United European Gastroenterol J 2014; 1: 438-444
    CrossrefPubMedGoogle Scholar